Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P mutated diffuse large B-cell lymphoma: analysis of 361 cases.

Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, Maingonnat C, Mareschal S, Picquenot JM, Penther D, Jais JP, Tesson B, Peyrouze P, Figeac M, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Fabiani B, Delarue R, Peyrade F, André M, Ketterer N, Leroy K, Salles G, Molina TJ, Tilly H, Jardin F.

Clin Cancer Res. 2016 Dec 6. pii: clincanres.1922.2016. [Epub ahead of print]

PMID:
27923841
2.

Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).

Voegeli M, Rondeau S, Berardi Vilei S, Lerch E, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M.

Hematol Oncol. 2016 Sep 28. doi: 10.1002/hon.2348. [Epub ahead of print]

PMID:
27677906
3.

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G.

Hematol Oncol. 2016 Jun 10. doi: 10.1002/hon.2305. [Epub ahead of print]

PMID:
27282998
4.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.

Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc-Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, Salles G, Brice P, Bouscary D, Deau B, Tamburini J.

Leuk Lymphoma. 2016 Dec;57(12):2820-2826.

PMID:
27118302
5.

Can Low Dose Radiation Therapy (2 × 2 Gy) be Used in Primary Bilateral Conjunctival Follicular Lymphoma?

Cotting-Bodmer S, Moulin A, Herbort CP Jr, Ketterer N, Betz M, Pica A, Schalenbourg A.

Klin Monbl Augenheilkd. 2016 Apr;233(4):524-6. doi: 10.1055/s-0041-111824. No abstract available.

PMID:
27116528
6.

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.

Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, Maingonnat C, Jais JP, Peyrouze P, Figeac M, Molina TJ, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Salles G, Tilly H, Leroy K, Jardin F.

Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305.

PMID:
26819451
7.

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.

Copie-Bergman C, Cuillière-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P.

Blood. 2015 Nov 26;126(22):2466-74. doi: 10.1182/blood-2015-05-647602.

8.

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C.

Bone Marrow Transplant. 2016 Jan;51(1):51-7. doi: 10.1038/bmt.2015.213.

PMID:
26367239
9.

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

Samaras P, Bargetzi M, Betticher DC, Duchosal MA, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Taverna C, Zander T, Renner C.

Swiss Med Wkly. 2015 Feb 21;145:w14100. doi: 10.4414/smw.2015.14100. Review.

10.

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR.

J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866.

11.

High-dose therapy and autologous hematopoietic stem cell transplant in T-cell lymphoma: a single center experience.

Cairoli A, Ketterer N, Barelli S, Duchosal MA.

Leuk Lymphoma. 2014 Aug;55(8):1827-31. doi: 10.3109/10428194.2013.852666.

PMID:
24138331
12.

Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

Buchegger F, Mach JP, Press OW, Bischof Delaloye A, Larson SM, Prior JO, Ketterer N.

Ann Oncol. 2013 Jul;24(7):1948-9. doi: 10.1093/annonc/mdt198. No abstract available.

13.

Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.

Jardin F, Delfau-Larue MH, Molina TJ, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Jais JP, Figeac M, Leroy K, Mareschal S, Salles GA, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Haioun C, Tilly H.

Leuk Lymphoma. 2013 Sep;54(9):1898-907. doi: 10.3109/10428194.2013.767456.

PMID:
23327290
14.

In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.

Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D; CLWP of the EBMT..

Bone Marrow Transplant. 2013 Jul;48(7):966-71. doi: 10.1038/bmt.2012.257.

PMID:
23241739
15.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C.

Ann Oncol. 2013 Apr;24(4):1032-7. doi: 10.1093/annonc/mds600.

16.

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B.

J Clin Oncol. 2012 Dec 20;30(36):4462-9. doi: 10.1200/JCO.2012.41.9416.

17.

Fertility preservation in cancer patients. Review of the French speaking part of Switzerland and recommendations for different situations.

Wunder D, Perey L; Réseau Romand Cancer et Fertilité., Achtari C, Ambrosetti A, Bellavia M, Delaloye JF, de Ziegler D, Gumy-Pause F, Helg C, Ketterer N, Petignat P, Primi MP, Rosselet-Christ A, Zaman K.

Swiss Med Wkly. 2012 Oct 1;142:w13645. doi: 10.4414/smw.2012.13645. Review.

18.

Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better tolerance.

Buchegger F, Prior JO, Allenbach G, Baechler S, Kosinski M, Helg C, Chalandon Y, Ratib O, Delaloye AB, Ketterer N.

Clin Nucl Med. 2012 Oct;37(10):960-4. doi: 10.1097/RLU.0b013e318251e3af.

PMID:
22955069
19.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G.

J Clin Oncol. 2012 Jul 10;30(20):2475-82. doi: 10.1200/JCO.2011.37.4918. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. J Clin Oncol. 2014 Apr 20;32(12):1285.

PMID:
22585692
20.

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators..

N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.

Items per page

Supplemental Content

Loading ...
Support Center